Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Tandem Diabetes Care Inc is a medical devices business based in the US. Tandem Diabetes Care shares (TNDM) are listed on the NASDAQ and all prices are listed in US Dollars. Tandem Diabetes Care employs 2,000 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $61.81 |
|---|---|
| 52-week range | $52.69 - $155.86 |
| 50-day moving average | $72.19 |
| 200-day moving average | $111.86 |
| Wall St. target price | $136.45 |
| PE ratio | 686.7778 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.09 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $61.81 from 2022-07-01
| 1 week (2022-06-28) | 2.44% |
|---|---|
| 1 month (2022-06-02) | -7.98% |
| 3 months (2022-04-05) | -48.80% |
| 6 months (2022-01-01) | N/A |
| 1 year (2021-07-02) | -37.32% |
|---|---|
| 2 years (2020-07-02) | -37.30% |
| 3 years (2019-07-05) | 64.82 |
| 5 years (2017-07-05) | 7,621.42% |
Valuing Tandem Diabetes Care stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Tandem Diabetes Care's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Tandem Diabetes Care's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 687x. In other words, Tandem Diabetes Care shares trade at around 687x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Tandem Diabetes Care's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $24.5 million.
The EBITDA is a measure of a Tandem Diabetes Care's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $737.7 million |
|---|---|
| Operating margin TTM | 1.43% |
| Gross profit TTM | $376.2 million |
| Return on assets TTM | 0.75% |
| Return on equity TTM | 1.57% |
| Profit margin | 0.8% |
| Book value | $6.84 |
| Market capitalisation | $4 billion |
TTM: trailing 12 months
We're not expecting Tandem Diabetes Care to pay a dividend over the next 12 months.
Tandem Diabetes Care's shares were split on a 1:10 basis on 9 October 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Tandem Diabetes Care shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Tandem Diabetes Care shares which in turn could have impacted Tandem Diabetes Care's share price.
Over the last 12 months, Tandem Diabetes Care's shares have ranged in value from as little as $52.685 up to $155.86. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tandem Diabetes Care's is 0.6679. This would suggest that Tandem Diabetes Care's shares are less volatile than average (for this exchange).
Tandem Diabetes Care, Inc. , a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.